INVESTOR RELATIONS - Vertican Growth

INVESTOR RELATIONS

Key values

Ten hectares

Three licenses for cultivation THC and CBD flowers, drying, ethanolic extraction, CO2 extraction, fractioning of compounds, development of pharmaceutical formulations.

Team.

Low taxed revenues.

Located in a country that is an international logistic hub for the LATAM region.

Efficient internal logistic location of the sub-companies.

Alliance with the National University of chemistry.

Experienced team on medical cannabis industry.

GMPE-EU standard labs.

Vertical chain.

Cannabis friendly banking system.

Commercial LOI.

Puchrase of 12.5 mm shares.

Master plan of Algamur.

Production in a free zone, with MERCOSUR origin.

Sunlight range.

National work experience on pharma industry and agronomic production.

Indoor production in compliance with GAP and high standards regarding the microbiological content and contamination of the flowers.

Standardized production.

Social impact agreements.

Own independent clean water resource.

Control over each product traceability.

Biggest and only vertical project in Uruguay with no competitors for the whole chain.

No performance loss because of currency volatility.

Highly protected facilities and transport by international security company 24/7 video controlled.

Insurances of facilities.

High quality European GMP equipment and heavy duty facilities.

Highly trained and motivated management team and staff. Ongoing educational and multilingual programs.

Capital requirements

Investment required for each of the companies

39%

ALGAMUR

$ 7.742.200

19%

WEMBLAR

$ 3.764.000

26%

DUKILU TRADE

$ 5.250.000

16%

WORKING CAPITAL

$ 3.243.800

TOTAL INVESTMENT $ 20.000.000

Investment overview

The total inversion of Vertican´s subsidiaries will be of USD 20.000.000.

Algamur S.A. is the subsidiary which requires a bigger economic effort, since it is in charge of the primary production. This represents 39% of the total value of the project inversions, and it is followed by Dukilu Trade S.A with 19%, and then by Wemblar Corp. S.A. with 26%. The principal expenditures of these subsidiaries are on the teams and infrastructure, which are required to meet the EU-GMP certifications needed in order to meet higher selling prices than the competitors.

REVENEUE

COMPANY	FIRST YEAR	SECOND YEAR	THIRD YEAR
ALGAMUR	0	2,108,340	2,519,400
WEBLAR	0	4,753,544	6,164,795
DUKILU	0	7,009,525	9,360,793
TOTAL REVENUE	0	13,871,409	18,044,988

COSTS

COMPANY	FIRST YEAR	SECOND YEAR	THIRD YEAR
ALGAMUR	(535,200)	(1,803,234)	(1,926,946)
WEBLAR	(388,719)	(3,446,033)	(4,140,027)
DUKILU	(716,908)	(6,585,219)	(8,383,847)
TOTAL COSTS	(1,640,827)	(11,834,486)	(14,450,820)

PROFIT

COMPANY	FIRST YEAR	SECOND YEAR	THIRD YEAR
ALGAMUR	(535,200)	228,830	444,341
WEBLAR	(388,719)	1,307,512	2,024,768
DUKILU	(716,908)	424,306	976,946
TOTAL PROFIT	(1,640,827)	1,960,647	3,446,055

Investors Contact

If you are interested in receiving more information on the project, leave us your e-mail address here: